RxDoctor Payments Data

Ruma Dahal, MD

Adult Medicine · Winchester, VANPI 1376858498

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Merck at 37.9% of the total. That places this record below the midpoint for adult medicine clinicians in VA, where the typical reported total is $357.

$214in general payments, 2019–2025

Across 14 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$81
  • Philips North America LLC$42
  • Pfizer$29
  • Otsuka America Pharmaceutical, Inc.$16
  • E.r. Squibb & Sons, L.L.C.$16
  • Novartis$15
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$214100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$214 in reported general payments places this provider in the 45th percentile of 32 adult medicine providers in Virginia.

See all adult medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$293,667
Medicare patients
502
Services billed
8,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$136,532
OzempicSemaglutide91$103,309
TrulicityDulaglutide70$80,971
JardianceEmpagliflozin34$45,177
JanuviaSitagliptin Phosphate39$42,074
MounjaroTirzepatide37$39,436
XareltoRivaroxaban29$30,149
RybelsusSemaglutide13$23,422
MyrbetriqMirabegron26$17,780
Breo ElliptaFluticasone/Vilanterol29$16,133
ShingrixVaricella-Zoster Ge/As01b/Pf59$12,885
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$12,131
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,433
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$10,710
Lantus SolostarInsulin Glargine,hum.Rec.Anlog83$9,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$29$139,391139 claims
MerckJanuvia$81$42,07439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 32 adult medicine providers in Virginia.

Other adult medicine in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →